Cell-of-origin (GCB/ABC) and 7 genetic subgroups inform targeted strategies, yet R‑CHOP remains frontline; 30%–40% relapse or are refractory with poor salvage outcomes post-rituximab. Second-line ...
In patients with previously untreated diffuse large B-cell lymphoma (DLBCL), polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) demonstrated sustained ...
Matthew S. McKinney, MD, reflects on his first experience of treating a patient with diffuse large B-cell lymphoma (DLBCL) as a new attending at Duke University. The patient, a woman with multiple ...
The big question in administration of bispecific antibodies these days is how quickly they can move to the outpatient setting ...
The combination of Epkinly and R-mini-CHOP showed a 93% ORR and 86% CR rate in elderly DLBCL patients. At two years, 79% of patients remained in complete response, with a 76% progression-free survival ...
At the recent American Society of Hematology annual meeting, real-world analyses examined how polatuzumab vedotin (Polivy) with rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) is ...
Odronextamab combined with CHOP chemotherapy shows high efficacy in untreated DLBCL, with a 100% response rate at the 160 mg dose. The safety profile of odronextamab-CHOP is manageable, with common ...
Please provide your email address to receive an email when new articles are posted on . ORLANDO — In this video, Brian T. Hill, MD, PhD, discusses a study presented at ASH Annual Meeting and ...
—These investigators assessed the potential benefit of a high-risk signature to evaluate the molecular drivers of primary treatment resistance in patients with DLBCL. A recent study published in ...
Many people with an aggressive blood cancer called diffuse large B cell lymphoma are cured by the current gold standard of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results